Page last updated: 2024-08-23

staurosporine and su 11248

staurosporine has been researched along with su 11248 in 28 studies

Research

Studies (28)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	10 (35.71)	29.6817
2010's	17 (60.71)	24.3611
2020's	1 (3.57)	2.80

Authors

Authors	Studies
Atteridge, CE; Azimioara, MD; Benedetti, MG; Biggs, WH; Carter, TA; Ciceri, P; Edeen, PT; Fabian, MA; Floyd, M; Ford, JM; Galvin, M; Gerlach, JL; Grotzfeld, RM; Herrgard, S; Insko, DE; Insko, MA; Lai, AG; Lélias, JM; Lockhart, DJ; Mehta, SA; Milanov, ZV; Patel, HK; Treiber, DK; Velasco, AM; Wodicka, LM; Zarrinkar, PP	1
Giranda, VL; Johnson, EF; Luo, Y; Stewart, KD; Woods, KW	1
Bullock, AN; Fedorov, O; Knapp, S; Marsden, B; Müller, S; Pogacic, V; Rellos, P; Schwaller, J; Sundström, M	1
Atteridge, CE; Campbell, BT; Chan, KW; Ciceri, P; Davis, MI; Edeen, PT; Faraoni, R; Floyd, M; Gallant, P; Herrgard, S; Hunt, JP; Karaman, MW; Lockhart, DJ; Milanov, ZV; Morrison, MJ; Pallares, G; Patel, HK; Pritchard, S; Treiber, DK; Wodicka, LM; Zarrinkar, PP	1
Fales, HM; Gottesman, MM; Hall, MD; Hellawell, JL; Hibbs, DE; Kensler, CB; Ludwig, JA; Salam, NK; Szakács, G	1
Russu, WA; Shallal, HM	1
Andreani, A; Granaiola, M; Kondapaka, S; Lannigan, D; Leoni, A; Locatelli, A; Morigi, R; Rambaldi, M; Scudiero, D; Shoemaker, RH; Smith, J; Varoli, L	1
Hixon, MS; Hori, A; Imamura, S; Iwata, H; Kimura, H; Miki, H	1
Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP	1
Al-Mazaideh, GM; Erdmann, F; Göllner, C; Rohe, A; Schmidt, M; Sippl, W; Wichapong, K	1
Amombo, GM; Baumann, K; Fach, M; Göring, S; Kolb, S; Kramer, T; Lo Monte, F; Schmidt, B; Schubenel, R; Smith, S	1
Doddareddy, MR; Kassiou, M; Kavanagh, ME	1
Chang, PT; Chen, GS; Chern, JW; Jagtap, AD; Kondekar, NB; Liu, JR; Shen, LJ; Tseng, HW; Wang, HC	1
Chen, Y; Jiao, Y; Lu, T; Wang, L; Zhang, D; Zhang, Y	1
Chen, Y; Gao, L; Li, J; Lu, W; Shen, Q; Tong, L; Zhang, Q	1
Abdel-Aziz, AK; Abouzid, KAM; Dokla, EME; McPhillie, MJ; Milik, SN; Minucci, S	1
Kiyoi, H	1
von Mehren, M	1
Duyster, J; Grundler, R; Kancha, RK; Peschel, C	1
Bui, B; Italiano, A	1
Ehninger, G; Illmer, T	1
Levis, M; Murphy, KM; Pratz, KW; Rajkhowa, T; Sato, T; Stine, A	1
Ashman, LK; Griffith, R; Mashkani, B	1
Chabner, BA; Fathi, AT	1
Akita, K; Fujii, I; Gouda, M; Ishihama, Y; Kirii, Y; Kitagawa, D; Narumi, Y; Sugiyama, N; Yokota, K	1
Fiedler, W; Wellbrock, J	1
Albers, C; Duyster, J; Illert, AL; Leischner, H; Peschel, C; Verbeek, M; von Bubnoff, N; Yu, C	1
Bennett, KL; Borgdorff, V; Breitwieser, FP; Colinge, J; Gridling, M; Müller, AC; Rix, U; Superti-Furga, G; Wagner, C; Wagner, SN; Winter, GE	1

Reviews

5 review(s) available for staurosporine and su 11248

Article	Year
[Possibility of targeting FLT3 kinase for the treatment of leukemia]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2005, Volume: 46, Issue:3 Topics: Animals; Antibodies, Monoclonal; Benzoquinones; Carbazoles; Drug Design; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; Furans; Humans; Indoles; Lactams, Macrocyclic; Leukemia; Mutation; Piperazines; Pyrroles; Quinazolines; Quinones; Rifabutin; Staurosporine; Sunitinib	2005
Beyond imatinib: second generation c-KIT inhibitors for the management of gastrointestinal stromal tumors. Clinical colorectal cancer, 2006, Volume: 6 Suppl 1 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Bevacizumab; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Everolimus; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunosuppressive Agents; Indoles; Niacinamide; Oligonucleotides; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sirolimus; Staurosporine; Sunitinib; Thiazoles	2006
[Gastrointestinal stromal tumors: molecular aspects and therapeutic implications]. Bulletin du cancer, 2008, Volume: 95, Issue:1 Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Disease Progression; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Neoplasm Proteins; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperazines; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sorafenib; Staurosporine; Sunitinib; Thiazoles	2008
FLT3 kinase inhibitors in the management of acute myeloid leukemia. Clinical lymphoma & myeloma, 2007, Volume: 8 Suppl 1 Topics: Benzenesulfonates; Carbazoles; Clinical Trials as Topic; fms-Like Tyrosine Kinase 3; Furans; Humans; Indoles; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Sorafenib; Staurosporine; Sunitinib	2007
Clinical experience with antiangiogenic therapy in leukemia. Current cancer drug targets, 2011, Volume: 11, Issue:9 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Clinical Trials as Topic; Humans; Indoles; Lenalidomide; Leukemia; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sorafenib; Staurosporine; Sunitinib; Thalidomide; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A	2011

Other Studies

23 other study(ies) available for staurosporine and su 11248

Article	Year
A small molecule-kinase interaction map for clinical kinase inhibitors. Nature biotechnology, 2005, Volume: 23, Issue:3 Topics: Benzamides; Drug Design; Escherichia coli; Escherichia coli Proteins; Imatinib Mesylate; Microchemistry; Pharmaceutical Preparations; Piperazines; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Pyrimidines	2005
Pharmacological and functional comparison of the polo-like kinase family: insight into inhibitor and substrate specificity. Biochemistry, 2007, Aug-21, Volume: 46, Issue:33 Topics: Adenosine Triphosphate; Amino Acid Sequence; Androstadienes; Binding Sites; Cell Cycle Proteins; Humans; Models, Molecular; Molecular Sequence Data; Peptide Library; Polo-Like Kinase 1; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Substrate Specificity; Wortmannin	2007
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proceedings of the National Academy of Sciences of the United States of America, 2007, Dec-18, Volume: 104, Issue:51 Topics: Amino Acid Sequence; Binding Sites; Clinical Trials as Topic; Drug Evaluation, Preclinical; Enzyme Stability; Humans; Molecular Sequence Data; Phylogeny; Protein Array Analysis; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases	2007
A quantitative analysis of kinase inhibitor selectivity. Nature biotechnology, 2008, Volume: 26, Issue:1 Topics: Binding Sites; Enzyme Activation; Humans; Phosphotransferases; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Proteome; Quantitative Structure-Activity Relationship	2008
Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells. Journal of medicinal chemistry, 2009, May-28, Volume: 52, Issue:10 Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Death; Cytotoxins; Drug Resistance, Multiple; Enzyme Inhibitors; HeLa Cells; Humans; Hydrophobic and Hydrophilic Interactions; Indoles; Isatin; Quantitative Structure-Activity Relationship; Substrate Specificity	2009
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives. European journal of medicinal chemistry, 2011, Volume: 46, Issue:6 Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Stereoisomerism; Structure-Activity Relationship	2011
Imidazo[2,1-b]thiazole guanylhydrazones as RSK2 inhibitors. European journal of medicinal chemistry, 2011, Volume: 46, Issue:9 Topics: Cell Line, Tumor; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Glycogen Synthase Kinase 3; Humans; Hydrazones; Magnetic Resonance Spectroscopy; Ribosomal Protein S6 Kinases; Spectrophotometry, Infrared	2011
Biochemical characterization of a novel type-II VEGFR2 kinase inhibitor: comparison of binding to non-phosphorylated and phosphorylated VEGFR2. Bioorganic & medicinal chemistry, 2011, Sep-15, Volume: 19, Issue:18 Topics: Binding Sites; Cells, Cultured; Humans; Phosphorylation; Protein Kinase Inhibitors; Structure-Activity Relationship; Time Factors; Vascular Endothelial Growth Factor Receptor-2	2011
Comprehensive analysis of kinase inhibitor selectivity. Nature biotechnology, 2011, Oct-30, Volume: 29, Issue:11 Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity	2011
Evaluation of potential Myt1 kinase inhibitors by TR-FRET based binding assay. European journal of medicinal chemistry, 2013, Volume: 61 Topics: Dose-Response Relationship, Drug; Fluorescence Resonance Energy Transfer; Glycolipids; Humans; Membrane Proteins; Models, Molecular; Molecular Structure; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Structure-Activity Relationship	2013
Modification of a promiscuous inhibitor shifts the inhibition from γ-secretase to FLT-3. Bioorganic & medicinal chemistry letters, 2012, Dec-15, Volume: 22, Issue:24 Topics: Amyloid Precursor Protein Secretases; Animals; Dose-Response Relationship, Drug; Embryo, Nonmammalian; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; Humans; Molecular Structure; Phenotype; Recombinant Proteins; Structure-Activity Relationship; Substrate Specificity; Zebrafish	2012
The development of CNS-active LRRK2 inhibitors using property-directed optimisation. Bioorganic & medicinal chemistry letters, 2013, Jul-01, Volume: 23, Issue:13 Topics: Central Nervous System; Central Nervous System Agents; Dose-Response Relationship, Drug; Drug Discovery; High-Throughput Screening Assays; Humans; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Molecular Structure; Morpholines; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrimidines; Structure-Activity Relationship	2013
Novel acylureidoindolin-2-one derivatives as dual Aurora B/FLT3 inhibitors for the treatment of acute myeloid leukemia. European journal of medicinal chemistry, 2014, Oct-06, Volume: 85 Topics: Animals; Antineoplastic Agents; Aurora Kinase B; Cell Line, Tumor; Chlorocebus aethiops; Drug Design; fms-Like Tyrosine Kinase 3; Humans; Indoles; Leukemia, Myeloid, Acute; Male; Mice; Protein Kinase Inhibitors; Vero Cells; Xenograft Model Antitumor Assays	2014
Discovery of Novel Potent VEGFR-2 Inhibitors Exerting Significant Antiproliferative Activity against Cancer Cell Lines. Journal of medicinal chemistry, 2018, 01-11, Volume: 61, Issue:1 Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Inhibitory Concentration 50; Molecular Docking Simulation; Protein Conformation; Protein Kinase Inhibitors; Structure-Activity Relationship; Vascular Endothelial Growth Factor Receptor-2	2018
Pyrazolo[4,3-b]pyrimido[4,5-e][1,4]diazepine derivatives as new multi-targeted inhibitors of Aurora A/B and KDR. European journal of medicinal chemistry, 2018, Oct-05, Volume: 158 Topics: Animals; Antineoplastic Agents; Aurora Kinase A; Aurora Kinase B; Azepines; Cell Line, Tumor; Humans; Mice; Mice, Nude; Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Vascular Endothelial Growth Factor Receptor-2	2018
Discovery of a benzimidazole-based dual FLT3/TrKA inhibitor targeting acute myeloid leukemia. Bioorganic & medicinal chemistry, 2022, 02-15, Volume: 56 Topics: Antineoplastic Agents; Apoptosis; Benzimidazoles; Cell Line; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; fms-Like Tyrosine Kinase 3; Humans; Models, Molecular; Molecular Structure; Protein Kinase Inhibitors; Receptor, trkA; Structure-Activity Relationship	2022
Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations. Experimental hematology, 2007, Volume: 35, Issue:10 Topics: Antineoplastic Agents; Benzenesulfonates; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; fms-Like Tyrosine Kinase 3; Humans; Indoles; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Staurosporine; Sunitinib	2007
FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML. Blood, 2010, Feb-18, Volume: 115, Issue:7 Topics: Alleles; Antineoplastic Agents; Benzenesulfonates; Benzothiazoles; Carbazoles; Cell Death; Cell Line, Tumor; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Furans; Humans; Indazoles; Indoles; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Pyridines; Pyrroles; Sorafenib; Staurosporine; Sunitinib	2010
Colony stimulating factor-1 receptor as a target for small molecule inhibitors. Bioorganic & medicinal chemistry, 2010, Mar-01, Volume: 18, Issue:5 Topics: Benzamides; Binding Sites; Carbazoles; Computer Simulation; Dasatinib; Drug Design; Furans; Humans; Hydrogen Bonding; Imatinib Mesylate; Indoles; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptor, Macrophage Colony-Stimulating Factor; Staurosporine; Sunitinib; Thiazoles	2010
FLT3 inhibition as therapy in acute myeloid leukemia: a record of trials and tribulations. The oncologist, 2011, Volume: 16, Issue:8 Topics: Antineoplastic Agents; Benzothiazoles; Carbazoles; Clinical Trials as Topic; Cytokines; fms-Like Tyrosine Kinase 3; Furans; Humans; Indoles; Leukemia, Myeloid, Acute; Phenylurea Compounds; Pyrroles; Staurosporine; Sunitinib; Tandem Repeat Sequences	2011
Characterization of kinase inhibitors using different phosphorylation states of colony stimulating factor-1 receptor tyrosine kinase. Journal of biochemistry, 2012, Volume: 151, Issue:1 Topics: Animals; Benzamides; Benzenesulfonates; Binding, Competitive; Cell Line; Dasatinib; Dose-Response Relationship, Drug; Humans; Imatinib Mesylate; Indazoles; Indoles; Kinetics; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Receptor, Macrophage Colony-Stimulating Factor; Sorafenib; Spodoptera; Staurosporine; Sulfonamides; Sunitinib; Surface Plasmon Resonance; Thiazoles; Transfection	2012
The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia, 2013, Volume: 27, Issue:6 Topics: Antineoplastic Agents; Benzothiazoles; Drug Resistance, Neoplasm; Female; fms-Like Tyrosine Kinase 3; Humans; Indoles; Leukemia, Myeloid, Acute; Middle Aged; Mutation; Phenylurea Compounds; Pyrroles; Staurosporine; Sunitinib	2013
A chemical biology approach identifies AMPK as a modulator of melanoma oncogene MITF. Oncogene, 2014, May-08, Volume: 33, Issue:19 Topics: AMP-Activated Protein Kinases; Blotting, Western; Cell Line; Cell Survival; Chromatography, Liquid; Enzyme Inhibitors; Fluorescent Antibody Technique; Humans; Indoles; Mass Spectrometry; Melanocytes; Melanoma; Microphthalmia-Associated Transcription Factor; Oncogenes; Pyrroles; RNA Interference; RNA, Small Interfering; Staurosporine; Sunitinib; Transfection	2014